Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2020

Open Access 01-12-2020 | Fertility | Case report

Elevated CA 125 level in a mucinous cystadenoma and a teratoma: a case report

Authors: Chanil Deshan Ekanayake, Nayoman Munasinghe, Iranthi Kumarasinghe, Sachini Rasnayake

Published in: Journal of Medical Case Reports | Issue 1/2020

Login to get access

Abstract

Background

The presence of a suspicious ovarian cyst with elevated cancer antigen 125 level in a woman of reproductive age poses a serious therapeutic dilemma. Mature cystic teratomas and mucinous cystadenomas may also cause an increase in cancer antigen 125.

Case presentation

A 43-year-old Sinhalese woman with a history of anovulatory subfertility for 5 years presented with heavy menstrual bleeding and secondary dysmenorrhea of 6 months’ duration. Imaging (pelvic ultrasound and computed tomography of the abdomen and pelvis) revealed a hemorrhagic cyst (6 × 4 cm) on the right side and a multilocular cyst with solid areas (10 × 7 cm) on the left side. Her cancer antigen 125 level was 2715 U/ml. Following a multidisciplinary team meeting, a fertility-sparing staging laparotomy was performed, which included right cystectomy, left oophorectomy, infracolic omentectomy, and peritoneal washings. Histology revealed a mucinous cystadenoma of the right ovary and a mature cystic teratoma on the left ovary. No malignant cells were observed in peritoneal washings. The patient’s cancer antigen 125 level dropped to 74.8 U/ml 1 month after surgery.

Conclusion

Rarely, teratomas and mucinous cystadenomas may also give rise to an extremely high cancer antigen 125 level. The risk of malignancy index and risk of malignancy algorithm may both be misleading in these instances. Therefore, multidisciplinary input, fertility-sparing surgery, and follow-up are paramount to achieve optimal treatment and patient satisfaction.
Literature
1.
go back to reference Kumar V, Abbas AK, Aster JC. Female genital system and breast. In: Robbins basic pathology. 9th ed. Philadelphia: Elsevier; 2013. p. 698–700. Kumar V, Abbas AK, Aster JC. Female genital system and breast. In: Robbins basic pathology. 9th ed. Philadelphia: Elsevier; 2013. p. 698–700.
2.
go back to reference Rao S, Kapurubandara S, Anpalagan A. Elevated CA 125 in a case of leaking endometrioma. Case Rep Obstet Gynecol. 2018;2018:2385048.PubMedPubMedCentral Rao S, Kapurubandara S, Anpalagan A. Elevated CA 125 in a case of leaking endometrioma. Case Rep Obstet Gynecol. 2018;2018:2385048.PubMedPubMedCentral
3.
go back to reference Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15:274–81.CrossRef Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15:274–81.CrossRef
5.
go back to reference Cho HY, Kim K, Jeon YT, Kim YB. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma. Med Sci Monit. 2013;19:230–5.CrossRef Cho HY, Kim K, Jeon YT, Kim YB. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma. Med Sci Monit. 2013;19:230–5.CrossRef
6.
go back to reference Dong L, Cui H, Li XP, et al. Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2008;43:5–8.PubMed Dong L, Cui H, Li XP, et al. Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2008;43:5–8.PubMed
7.
go back to reference Royal College of Obstetricians and Gynaecologists. Fertility-sparing treatments in gynaecological cancers. Scientific impact paper no. 35. 2013. Royal College of Obstetricians and Gynaecologists. Fertility-sparing treatments in gynaecological cancers. Scientific impact paper no. 35. 2013.
8.
go back to reference Lycke M, Kristjansdottire B, Sundfeldt KA. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151:159–65.CrossRef Lycke M, Kristjansdottire B, Sundfeldt KA. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151:159–65.CrossRef
Metadata
Title
Elevated CA 125 level in a mucinous cystadenoma and a teratoma: a case report
Authors
Chanil Deshan Ekanayake
Nayoman Munasinghe
Iranthi Kumarasinghe
Sachini Rasnayake
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2020
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-020-02458-x

Other articles of this Issue 1/2020

Journal of Medical Case Reports 1/2020 Go to the issue